BioAtla LLC, a global biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapy, today announced the Global BIO Impact Fund (Global BIO), U. Oh, S -based Bioscience Investment Fund, committed to invest $45 million in BioAtla. The investment will be $15 million in BioAtla’s equity by the end of January 2016 and $30 million by the end of March 2016 in direct funding for the early development of several CAB antibody candidates for BioAtla’s proprietary portfolio. Through program funding, Global BIO will share the risks and potential returns of BioAtla’s first four CAB candidates who will receive U approval for Investigational New Drugs (IND) Oh, S Administration of Food and Drugs
Specific CAB candidates under the Global BIO Agreement would be part of BioAtla’s decision and could include CAB products under development under BioAtla’s May 2015 collaboration with Beijing Sinobioway Group Company Limited (Sinobioway) or BioAtla CAB-ADC products under the December 2015 BioAtla agreement with Pfizer Inc. Or other products of BioAtla CAB under consideration BioAtla and Sinobioway work collaboratively to develop several CAB candidates. Sinobioway has exclusive rights to and will fund the development, manufacturing, clinical trials and marketing costs of selected CAB antibodies in China, Hong Kong, Macau and Taiwan. BioAtla retains the rights of the rest of the world (ROW) to these products The Pfizer Agreement advances the development and commercialization of a new class of antibody therapy based on BioAtla’s CAB platform and using Pfizer’s proprietary antibody drug conjugate (ADC) payload. Under the agreement, BioAtla and Pfizer will each have a license to pursue the development and commercialization of several CAB-ADC antibodies to their respective technology.
This investment by Global BIO, in particular the non-dilution funding of $30 million for program development, is an important component of BioAtla’s strategy to build a robust proprietary portfolio of novel cancer therapy based on the CAB platform. BioAtla’s patent protected Conditionally Active Biologics platform is a disruptive technology for the development of a powerful new class of immunotherapy that is activated in selected microenvironments within the body, such as those that are indicative of cancerous tumors. CABs may be generated in a variety of formats, including bare monoclonal antibodies (mAbs), antibody drug conjugates, immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T cells.
‘BioAtla’s strategy is to maintain control of the development and prospects of its CAB candidates, potentially through commercialization, to maximize the value of our equity holders and to allow BioAtla to pursue the therapeutic strategies of CAB combinations made possible by CAB technology,’ said Jay M. Short, Ph.D. D. D. , Chairman, Chief Executive Officer and Chairman of the Board of BioAtla ‘We are expanding our strategy with collaborations in key specific geographic markets such as China and key technology agreements such as ADCs. Development efficiency and cost-effective financing, such as that provided by Global BIO, are key elements of our plans ”
Global BIO Impact Fund managers are committed to accelerating the delivery of disruptive technologies to the world – across the spectrum from life sciences and medicine to agriculture – to enhance the future of people everywhere, according to John Evey, co-managing director of the Global BIO Impact Fund. ‘The rapid advancement of BioAtla’s novel cancer antibody development technology is directly aligned with our Global BIO strategy, and the fund’s managers are pleased to help deliver a new generation of cancer therapy to patients worldwide. ”
About Conditionally Active Biologics (CAB)
Conditionally Active Biologic proteins are produced using BioAtla’s proprietary protein evolution and expression technologies. These proteins may be mAbs, enzymes and other proteins designed to function on the basis of changes in microphysiological conditions (e) g The g , pH, oxidation, temperature, pressure, presence of certain ions, hydrophobicity and combinations thereof)
Studies have shown that cancerous tumors create highly specific conditions at their site that are not present in normal tissues. These cancerous microenvironments are primarily the result of the well-understood unique glycolytic metabolism associated with cancer cells, referred to as the Warburg Effect, which was first described in the early 1900s and is the basis of the widely used PET cancer screening method. CAB-designed mAbs may be programmed to deliver their therapeutic payload and/or to recruit immune response at specific and selected locations and conditions within the body. CABs increase safety because the drug’s activation depends on its presence in a particular cellular microenvironment and therefore preferably binds to its target protein in the disease area. In addition, activation is reversible and can be switched on and off repeatedly if the CAB product moves from the diseased to the normal cellular microenvironment and vice versa further reduces the chance that the CAB would bind to the same protein located in healthy tissues or in other parts of the body and cause undesirable toxicity.
CABs allow higher dosing, the development of effective, non-immunogenic drugs, and the use of targets validated for cancer cells but traditionally considered too prevalent among normal cells to be used safely in current drug therapies. This opens up a potentially rich set of targets for CABs that cannot be addressed using existing technologies CABs may also be used as diagnostic tools to detect and detect conditions that are indicative of cancer activity.
Global BIO Impact Fund
Organized to give investors the opportunity to make exceptional financial returns while stimulating positive change by accelerating the development and global adoption of disruptive bioscience technologies, the Global BIO Impact Fund, U. Oh, S The California-based investment fund was founded by five individuals with extensive experience in biotechnology, corporate governance, entrepreneurship, medicine, real estate fund management, impact investment and the non-profit sector. Global BIO managers derive additional insight and guidance from Code Blue Innovations and MedSci International, an entity that facilitates international equity investment and joint venture partnerships for American companies with disruptive technologies that will enhance the future.
About LLC BioAtla
BioAtla is a global biotech company with operations in San Diego, California and Beijing, China. BioAtla develops novel monoclonal antibody and other protein therapeutic products with more selective targeting, greater efficacy and more cost-effective and predictable manufacturing. By using its proprietary technologies for product design and development, from target discovery to manufacturing and preclinical studies, BioAtla develops differentiated, patentable therapeutic proteins for its partners and internal programmes. BioAtla has more than 100 patents issued and pending covering its platform technologies, which represent a complete complement to therapeutic protein development capabilities. Find out more at www Bioatla’s Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/BioAtla/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at firstname.lastname@example.org